PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
Status:
Active, not recruiting
Trial end date:
2023-05-11
Target enrollment:
Participant gender:
Summary
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the
safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp
hair loss due to Alopecia Areata (AA).